Invest in Eone Diagnomics: Low P/E & Rising Stock in Genomic Diagnostics
Explore how Eone Diagnomics, a KOSDAQ biotech leader in genomic diagnostics, is undervalued with a 2.3 P/E and 52‑week high, poised to drive precision medicine growth.
2 minutes to read